A new approach for elimination of apoptotic resistance caused by MDM2/MDMX amplification in chronic lymphocytic leukemia: combination of ALRN-6924 and radiofrequency exposure.
Berrak Kurt, Handan Kayhan, Elçin Özgür Büyükatalay, Görkem Kısmalı
AI summary
75% confidenceA new approach to eliminate apoptotic resistance in CLL using ALRN-6924 and radiofrequency exposure has been proposed, showing promising results in restoring p53 function and inducing apoptosis in CLL cell lines.
Generated by MESSAI extraction pipeline · review against source PDF
Representative MEC — matched on the paper’s system type only, not its reactor or geometry.
Reported parameters
No values extracted from this paper yet.
Open in lab for full controls, parameter editing, and template overlays.
Open in lab →What they did
- System
- MEC
What worked
No outcome metrics extracted yet.
Abstract
Chronic lymphocytic leukemia (CLL) is characterized by mature B lymphocyte accumulation and frequent MDM2/MDMX overexpression, leading to p53 inactivation and apoptotic resistance. ALRN-6924, a stapled peptide dual inhibitor, targets MDM2/MDMX to restore p53 function. This study evaluated ALRN-6924 efficacy alone and combined with radiofrequency (RF) exposure in CLL cell lines. Molecular docking assessed ALRN-6924-MDM2 binding affinity. Cytotoxic and apoptotic effects were evaluated using XTT assays and flow cytometry in HG-3 (wild-type p53) and MEC-1 (mutant p53) cell lines. Treatments included ALRN-6924 monotherapy and combination with 900 MHz RF exposure (120 mW/cm 2 ). MDM2, MDMX, BCL-2, and p53 protein levels were quantified by ELISA. Molecular docking revealed strong ALRN-6924-MDM2 binding (energy: - 9.30 kcal/mol, Ki: 163.9 nM). ALRN-6924 demonstrated potent cytotoxicity in HG-3 cells (IC 50 : 7.54 μM at 24 h, 5.88 μM at 48 h) versus resistance in MEC-1 cells (IC 50 : ~ 36 μM). In HG-3 cells, ALRN-6924 significantly induced apoptosis and necroptosis, reduced MDM2/MDMX expression, and enhanced p53 levels. RF combination therapy showed synergistic effects, further improving efficacy compared to monotherapy. BCL-2 expression was significantly reduced in the combination group. ALRN-6924 demonstrates promising therapeutic potential in wild-type p53 CLL cells, with enhanced efficacy when combined with RF exposure. The compound effectively disrupts the MDM2/MDMX-p53 axis, restoring p53 function and inducing programmed cell death. In mutant p53 cells, combination therapy may provide partial benefits. These findings support ALRN-6924 clinical development as targeted therapy for p53-functional CLL, particularly in combination strategies.
Keywords
Identifiers
- PubMed
- 41385030
- Journal
- Medical oncology (Northwood, London, England)
- Year
- 2025